<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:05:07Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5464557" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5464557</identifier><datestamp>2017-06-22</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, CA USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5464557</article-id>
      <article-id pub-id-type="pmcid">PMC5464557</article-id>
      <article-id pub-id-type="pmc-uid">5464557</article-id>
      <article-id pub-id-type="pmid">28594869</article-id>
      <article-id pub-id-type="pmid">28594869</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0178125</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-16-40569</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Bioenergetics</subject>
              <subj-group>
                <subject>Energy-Producing Organelles</subject>
                <subj-group>
                  <subject>Mitochondria</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Cell Biology</subject>
            <subj-group>
              <subject>Cellular Structures and Organelles</subject>
              <subj-group>
                <subject>Energy-Producing Organelles</subject>
                <subj-group>
                  <subject>Mitochondria</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Diagnostic Medicine</subject>
            <subj-group>
              <subject>Signs and Symptoms</subject>
              <subj-group>
                <subject>Atrophy</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Pathology and Laboratory Medicine</subject>
            <subj-group>
              <subject>Signs and Symptoms</subject>
              <subj-group>
                <subject>Atrophy</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Musculoskeletal System</subject>
              <subj-group>
                <subject>Limbs (Anatomy)</subject>
                <subj-group>
                  <subject>Arms</subject>
                  <subj-group>
                    <subject>Hands</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Musculoskeletal System</subject>
              <subj-group>
                <subject>Limbs (Anatomy)</subject>
                <subj-group>
                  <subject>Arms</subject>
                  <subj-group>
                    <subject>Hands</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Physiology</subject>
            <subj-group>
              <subject>Muscle Physiology</subject>
              <subj-group>
                <subject>Muscle Functions</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Physiology</subject>
            <subj-group>
              <subject>Muscle Physiology</subject>
              <subj-group>
                <subject>Muscle Functions</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Cell Biology</subject>
            <subj-group>
              <subject>Cellular Types</subject>
              <subj-group>
                <subject>Animal Cells</subject>
                <subj-group>
                  <subject>Connective Tissue Cells</subject>
                  <subj-group>
                    <subject>Fibroblasts</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Biological Tissue</subject>
              <subj-group>
                <subject>Connective Tissue</subject>
                <subj-group>
                  <subject>Connective Tissue Cells</subject>
                  <subj-group>
                    <subject>Fibroblasts</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Biological Tissue</subject>
              <subj-group>
                <subject>Connective Tissue</subject>
                <subj-group>
                  <subject>Connective Tissue Cells</subject>
                  <subj-group>
                    <subject>Fibroblasts</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Musculoskeletal System</subject>
              <subj-group>
                <subject>Muscles</subject>
                <subj-group>
                  <subject>Skeletal Muscles</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Anatomy</subject>
            <subj-group>
              <subject>Musculoskeletal System</subject>
              <subj-group>
                <subject>Muscles</subject>
                <subj-group>
                  <subject>Skeletal Muscles</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Proteins</subject>
              <subj-group>
                <subject>Protein Domains</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Clinical Genetics</subject>
            <subj-group>
              <subject>Mitochondrial Diseases</subject>
              <subj-group>
                <subject>Lactic Acidosis</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Compound heterozygous mutations in glycyl-tRNA synthetase (<italic>GARS</italic>) cause mitochondrial respiratory chain dysfunction</article-title>
        <alt-title alt-title-type="running-head">GARS mutations cause mitochondrial dysfunction</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nafisinia</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Riley</surname>
            <given-names>Lisa G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gold</surname>
            <given-names>Wendy A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhattacharya</surname>
            <given-names>Kaustuv</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Broderick</surname>
            <given-names>Carolyn R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff006">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thorburn</surname>
            <given-names>David R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff007">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Simons</surname>
            <given-names>Cas</given-names>
          </name>
          <xref ref-type="aff" rid="aff008">
            <sup>8</sup>
          </xref>
          <xref ref-type="author-notes" rid="econtrib001">
            <sup>â¡</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8431-0641</contrib-id>
          <name>
            <surname>Christodoulou</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff007">
            <sup>7</sup>
          </xref>
          <xref ref-type="corresp" rid="cor001">*</xref>
          <xref ref-type="author-notes" rid="econtrib001">
            <sup>â¡</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff001"><label>1</label>
<addr-line>Genetic Metabolic Disorders Research Unit, Western Sydney Genetics Program, The Childrenâs Hospital at Westmead, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff002"><label>2</label>
<addr-line>Discipline of Child &amp; Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff003"><label>3</label>
<addr-line>Discipline of Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff004"><label>4</label>
<addr-line>Genetic Metabolic Disorders Service, Western Sydney Genetics Program, The Childrenâs Hospital at Westmead, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff005"><label>5</label>
<addr-line>Childrenâs Hospital Institute of Sports Medicine, The Childrenâs Hospital at Westmead, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff006"><label>6</label>
<addr-line>School of Medical Sciences, UNSW, Sydney, New South Wales, Australia</addr-line></aff>
      <aff id="aff007"><label>7</label>
<addr-line>Murdoch Childrens Research Institute and Victorian Clinical Genetics Services, Royal Childrenâs Hospital, and Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia</addr-line></aff>
      <aff id="aff008"><label>8</label>
<addr-line>Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, Australia</addr-line></aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Reddy</surname>
            <given-names>Hemachandra</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Texas Technical University Health Sciences Center, UNITED STATES</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="COI-statement" id="coi001">
          <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> MN WG LR JC.</p></list-item><list-item><p><bold>Data curation:</bold> MN CS.</p></list-item><list-item><p><bold>Formal analysis:</bold> MB WG LR CB DR CS JC.</p></list-item><list-item><p><bold>Funding acquisition:</bold> MN JC DT.</p></list-item><list-item><p><bold>Investigation:</bold> MN KB CB CS DT.</p></list-item><list-item><p><bold>Methodology:</bold> MN WG LR CB CS.</p></list-item><list-item><p><bold>Project administration:</bold> JC.</p></list-item><list-item><p><bold>Resources:</bold> KB CB CS JC DT.</p></list-item><list-item><p><bold>Software:</bold> MN LR WG CS.</p></list-item><list-item><p><bold>Supervision:</bold> JC.</p></list-item><list-item><p><bold>Validation:</bold> MN CB CS DT.</p></list-item><list-item><p><bold>Visualization:</bold> MN JC.</p></list-item><list-item><p><bold>Writing â original draft:</bold> MN WG LR CB KB CS DT.</p></list-item><list-item><p><bold>Writing â review &amp; editing:</bold> MN WG LR CB KB CS DT JC.</p></list-item></list>
</p>
        </fn>
        <fn fn-type="other" id="econtrib001">
          <p>â¡ These authors are co-senior authors on this work.</p>
        </fn>
        <corresp id="cor001">* E-mail: <email>john.christodoulou@mcri.edu.au</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>6</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <volume>12</volume>
      <issue>6</issue>
      <elocation-id>e0178125</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>10</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>5</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2017 Nafisinia et al</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>Nafisinia et al</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="pone.0178125.pdf"/>
      <abstract>
        <p>Glycyl-tRNA synthetase (<italic>GARS</italic>; OMIM 600287) is one of thirty-seven tRNA-synthetase genes that catalyses the synthesis of glycyl-tRNA, which is required to insert glycine into proteins within the cytosol and mitochondria. To date, eighteen mutations in <italic>GARS</italic> have been reported in patients with autosomal-dominant Charcot-Marie-Tooth disease type 2D (CMT2D; OMIM 601472), and/or distal spinal muscular atrophy type V (dSMA-V; OMIM 600794). In this study, we report a patient with clinical and biochemical features suggestive of a mitochondrial respiratory chain (MRC) disorder including mild left ventricular posterior wall hypertrophy, exercise intolerance, and lactic acidosis. Using whole exome sequencing we identified compound heterozygous novel variants, c.803C&gt;T; p.(Thr268Ile) and c.1234C&gt;T; p.(Arg412Cys), in <italic>GARS</italic> in the proband. Spectrophotometric evaluation of the MRC complexes showed reduced activity of Complex I, III and IV in patient skeletal muscle and reduced Complex I and IV activity in the patient liver, with Complex IV being the most severely affected in both tissues. Immunoblot analysis of GARS protein and subunits of the MRC enzyme complexes in patient fibroblast extracts showed significant reduction in GARS protein levels and Complex IV. Together these studies provide evidence that the identified compound heterozygous <italic>GARS</italic> variants may be the cause of the mitochondrial dysfunction in our patient.</p>
      </abstract>
      <funding-group>
        <award-group id="award001">
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
              <institution>National Health and Medical Research Council</institution>
            </institution-wrap>
          </funding-source>
          <award-id>1026891</award-id>
          <principal-award-recipient>
            <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8431-0641</contrib-id>
            <name>
              <surname>Christodoulou</surname>
              <given-names>John</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group id="award002">
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
              <institution>National Health and Medical Research Council</institution>
            </institution-wrap>
          </funding-source>
          <award-id>Principal Research Fellowship</award-id>
          <principal-award-recipient>
            <name>
              <surname>Thorburn</surname>
              <given-names>David R.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group id="award003">
          <funding-source>
            <institution>Australian Mitochondrial Disease Foundation</institution>
          </funding-source>
          <award-id>PhD Scholarship</award-id>
          <principal-award-recipient>
            <name>
              <surname>Nafisinia</surname>
              <given-names>Michael</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <funding-statement>We thank the Queensland Center for Medical Genomics and the IMB Sequencing Core for their assistance. This research was supported by Australian NHMRC grant 1026891 to J.C., an NHMRC Principal Research Fellowship to D.R.T., and an Australian Mitochondrial Disease Foundation (AMDF) PhD Scholarship to M.N. Finally, we also gratefully acknowledge donations to J.C. by the Crane and Perkins families.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="4"/>
        <page-count count="12"/>
      </counts>
      <custom-meta-group>
        <custom-meta id="data-availability">
          <meta-name>Data Availability</meta-name>
          <meta-value>The Sanger sequencing results for the mutations are described in the paper and the chromatograms are included in Figure 1. The whole exome sequence data (fastq files) cannot be made publicly available as data sharing was not included in the consent at the time the family was recruited to the project. Requests for these data can be sent to the corresponding author. This research project was administered by the Sydney Children's Hospitals Network Human Research Ethics Committee. Alternatively requests could be made to the Governance Officer (<email>SCHN-Governance@health.nsw.gov.au</email>) for release of data.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <title>Data Availability</title>
      <p>The Sanger sequencing results for the mutations are described in the paper and the chromatograms are included in Figure 1. The whole exome sequence data (fastq files) cannot be made publicly available as data sharing was not included in the consent at the time the family was recruited to the project. Requests for these data can be sent to the corresponding author. This research project was administered by the Sydney Children's Hospitals Network Human Research Ethics Committee. Alternatively requests could be made to the Governance Officer (<email>SCHN-Governance@health.nsw.gov.au</email>) for release of data.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec001">
      <title>Introduction</title>
      <p>Aminoacyl-tRNA synthetases (ARS) are ubiquitously expressed essential enzymes responsible for attaching amino acid residues to their cognate tRNA molecules, which is the first step of protein translation in the cytoplasm and mitochondria [<xref rid="pone.0178125.ref001" ref-type="bibr">1</xref>]. Human ARS proteins consist of three groups: cytoplasmic, mitochondrial, and bifunctional. For most ARS, the cytoplasmic and mitochondrial ARS for each amino acid are encoded by distinctly different nuclear genes. However, <italic>GARS</italic> (OMIM: 601472) and <italic>KARS</italic> (OMIM: 613641) encode both the cytoplasmic and mitochondrial ARS [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>]. It is noteworthy that nuclear genes encode the mitochondrial ARSs that are then imported into mitochondria [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>].</p>
      <p>The cytoplasmic and mitochondrial isoforms of glycyl-tRNA synthetase, encoded by <italic>GARS</italic>, differ by a 54 amino acid N-terminal mitochondrial targeting sequence [<xref rid="pone.0178125.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0178125.ref004" ref-type="bibr">4</xref>]. Mitochondrial GARS is required for the synthesis of 13 subunits of the MRC complexes, including subunits of Complex I, Complex III, Complex IV and Complex V [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>]. The human GARS belongs to the class IIA aminoacyl- tRNA synthetases, with the cytosolic isoform having 685 amino acids and the mitochondrial isoform having 739 amino acids [<xref rid="pone.0178125.ref004" ref-type="bibr">4</xref>]. Both isoforms include the N-terminal WHEP-TRS domain composed of the amino acid residues 62â122, a catalytic domain (124â608), and a C terminal anticodon-binding domain (602â726) [<xref rid="pone.0178125.ref004" ref-type="bibr">4</xref>].</p>
      <p>Missense mutations in <italic>GARS</italic> were first described in 2003 in association with Charcot-Marie-Tooth disease type 2D (CMT2D: OMIM 601472), and distal Spinal Muscular Atrophy type V (dSMA-V; OMIM 600794) in five families with atrophy and weakness of the hand muscles [<xref rid="pone.0178125.ref005" ref-type="bibr">5</xref>]. Several reports have since been published detailing pathogenic <italic>GARS</italic> missense mutations, mostly autosomal dominant, but some <italic>de novo</italic> [<xref rid="pone.0178125.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0178125.ref005" ref-type="bibr">5</xref>â<xref rid="pone.0178125.ref012" ref-type="bibr">12</xref>] (<xref rid="pone.0178125.t001" ref-type="table">Table 1</xref>).</p>
      <table-wrap id="pone.0178125.t001" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Clinical phenotypes associated with <italic>GARS</italic> variants in human.</title>
        </caption>
        <alternatives>
          <graphic id="pone.0178125.t001g" xlink:href="pone.0178125.t001"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">Kawakami<break/>et al. (2014)</th>
                <th align="left" rowspan="1" colspan="1">Del Bo<break/>et al. (2006)</th>
                <th align="left" rowspan="1" colspan="1">Antonellis<break/>et al. (2003)</th>
                <th align="left" rowspan="1" colspan="1">Rohkamm<break/>et al. (2007)</th>
                <th align="left" rowspan="1" colspan="1">Sivakumar<break/>et al. (2005) Antonellis<break/>et al. (2003)</th>
                <th align="left" rowspan="1" colspan="1">Sivakumar<break/>et al. (2005) Antonellis<break/>et al. (2003)</th>
                <th align="left" rowspan="1" colspan="1">Lee<break/>et al. (2012)</th>
                <th align="left" rowspan="1" colspan="1">Lee<break/>et al. (2012)</th>
                <th align="left" rowspan="1" colspan="1">Liao<break/>et al. (2015)</th>
                <th align="left" rowspan="1" colspan="1">Liao<break/>et al. (2015)</th>
                <th align="left" rowspan="1" colspan="1">Sivakumar<break/>et al. (2005) Antonellis<break/>et al. (2003)</th>
                <th align="left" rowspan="1" colspan="1">Hamaguchi<break/>et al. (2010)</th>
                <th align="left" rowspan="1" colspan="1">James<break/>et al. (2006)</th>
                <th align="left" rowspan="1" colspan="1">James<break/>et al. (2006)</th>
                <th align="left" rowspan="1" colspan="1">James<break/>et al. (2006)</th>
                <th align="left" rowspan="1" colspan="1">Klein<break/>et al. (2014)</th>
                <th align="left" rowspan="1" colspan="1">Sivakumar<break/>et al. (2005)</th>
                <th align="left" rowspan="1" colspan="1">Dubourg<break/>et al. (2006)</th>
                <th align="left" rowspan="1" colspan="1">McMillan<break/>at al. (2014)</th>
                <th align="left" rowspan="1" colspan="1">This Study</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GARS</italic><break/>variants</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.815T&gt;A p.Leu218Gln</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.2016G&gt;A<break/>p. Asp500Asn</td>
                <td align="left" rowspan="1" colspan="1"><break/>2094G&gt;C<break/>p. Gly526Arg</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.688 C &gt; T<break/>p.Ala57Val</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.730A&gt;G<break/>p.Glu71Gly</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.904C&gt;T<break/>p.Leu129Pro</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.598G&gt;A<break/>p. Asp200Asn</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.794C&gt;T<break/>p. Ser265Phe</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.598G&gt;T<break/>p. Asp146Tyr</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.875T&gt;G<break/>p.Met238Arg</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.1236G&gt;C<break/>p.Gly240Arg</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.893C&gt;T<break/>p. Pro244Leu</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.1358A&gt;T<break/>p.Ile280Phe</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.2313G&gt;C<break/>p.Gly598Ala</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.2260C&gt;T<break/>p. Ser581Leu</td>
                <td align="left" rowspan="1" colspan="1"><break/>p.Ile334Phe</td>
                <td align="left" rowspan="1" colspan="1"><break/>p.His418Arg</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.2094 A&gt;G<break/>p.Gly526Arg</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.1904C &gt; T<break/>p.Ser635Leu<break/>c.1787G &gt; A p.Arg596Gln</td>
                <td align="left" rowspan="1" colspan="1"><break/>c.803C&gt;T p.Thr268Ile<break/>c.1234C&gt;T<break/>p.Arg412Cys</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Inheritance</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">
                  <italic>De novo</italic>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <italic>De novo</italic>
                </td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">
                  <italic>De novo</italic>
                </td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AD</td>
                <td align="left" rowspan="1" colspan="1">AR</td>
                <td align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Protein<break/>domain potentially affected</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">Ins III</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">WD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">Ins I</td>
                <td align="left" rowspan="1" colspan="1">Ins III</td>
                <td align="left" rowspan="1" colspan="1">Ins I</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">ACBD</td>
                <td align="left" rowspan="1" colspan="1">ACBD</td>
                <td align="left" rowspan="1" colspan="1">Ins II</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
                <td align="left" rowspan="1" colspan="1">ACBD</td>
                <td align="left" rowspan="1" colspan="1">CD</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Phenotype</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">CMT2D/<break/>dSMA-V</td>
                <td align="left" rowspan="1" colspan="1">dSMA-V</td>
                <td align="left" rowspan="1" colspan="1">dHMN-V</td>
                <td align="left" rowspan="1" colspan="1">CMT2D/<break/>dSMA-V</td>
                <td align="left" rowspan="1" colspan="1">dSMA-V</td>
                <td align="left" rowspan="1" colspan="1">dHMN- V</td>
                <td align="left" rowspan="1" colspan="1">dHMN- V</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">CMT2D</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">dHMN- V</td>
                <td align="left" rowspan="1" colspan="1">Infantile SMA</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">CMT2</td>
                <td align="left" rowspan="1" colspan="1">dSMA-V</td>
                <td align="left" rowspan="1" colspan="1">dHMN-V</td>
                <td align="left" rowspan="1" colspan="1">MRCD</td>
                <td align="left" rowspan="1" colspan="1">MRCD</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Cohort</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">4 affected</td>
                <td align="left" rowspan="1" colspan="1">2 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">17 affected</td>
                <td align="left" rowspan="1" colspan="1">5 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">14 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">16 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
                <td align="left" rowspan="1" colspan="1">1 affected</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Age at<break/>onset</td>
                <td align="left" rowspan="1" colspan="1">&lt;2 Years</td>
                <td align="left" rowspan="1" colspan="1">10â35 Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">13â26 Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">12 Years</td>
                <td align="left" rowspan="1" colspan="1">18 Years (average)</td>
                <td align="left" rowspan="1" colspan="1">16.9 Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">15Years</td>
                <td align="left" rowspan="1" colspan="1">13Years</td>
                <td align="left" rowspan="1" colspan="1">&lt;6 months</td>
                <td align="left" rowspan="1" colspan="1">2 Years</td>
                <td align="left" rowspan="1" colspan="1">23 Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">10 Years</td>
                <td align="left" rowspan="1" colspan="1">11Years</td>
                <td align="left" rowspan="1" colspan="1">&lt;6 m</td>
                <td align="left" rowspan="1" colspan="1">27 Years</td>
                <td align="left" rowspan="1" colspan="1">24 Years</td>
                <td align="left" rowspan="1" colspan="1">26Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">23.3Years<break/>(average)</td>
                <td align="left" rowspan="1" colspan="1">7 Years</td>
                <td align="left" rowspan="1" colspan="1">6 Years</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Consanguinity</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="left" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">No</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">NS</td>
                <td align="justify" rowspan="1" colspan="1">No</td>
                <td align="justify" rowspan="1" colspan="1">No</td>
                <td align="justify" rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Ethnicity</td>
                <td align="left" rowspan="1" colspan="1">Japan</td>
                <td align="left" rowspan="1" colspan="1">Italy</td>
                <td align="left" rowspan="1" colspan="1">Sephardic<break/>Jewish</td>
                <td align="left" rowspan="1" colspan="1">Ghana</td>
                <td align="left" rowspan="1" colspan="1">Mongolia</td>
                <td align="left" rowspan="1" colspan="1">Bulgaria</td>
                <td align="left" rowspan="1" colspan="1">Korea</td>
                <td align="left" rowspan="1" colspan="1">Korea</td>
                <td align="left" rowspan="1" colspan="1">Taiwan</td>
                <td align="left" rowspan="1" colspan="1">Taiwan</td>
                <td align="left" rowspan="1" colspan="1">North America</td>
                <td align="left" rowspan="1" colspan="1">Japan</td>
                <td align="left" rowspan="1" colspan="1">UK</td>
                <td align="left" rowspan="1" colspan="1">UK</td>
                <td align="left" rowspan="1" colspan="1">UK</td>
                <td align="left" rowspan="1" colspan="1">USA</td>
                <td align="left" rowspan="1" colspan="1">UK/Australia</td>
                <td align="left" rowspan="1" colspan="1">France</td>
                <td align="left" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1">UK/Australia</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Clinical features</td>
                <td align="left" rowspan="1" colspan="1">delayed onset of walking, slow running</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">delayed milestones, severe generalised weakness</td>
                <td align="left" rowspan="1" colspan="1">delayed onset of walking, unsteady gait</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">slow running</td>
                <td align="left" rowspan="1" colspan="1">distal limb muscle atrophy and weakness</td>
                <td align="left" rowspan="1" colspan="1">delayed milestones, severe generalised weakness</td>
                <td align="left" rowspan="1" colspan="1">distal limb muscle weakness</td>
                <td align="left" rowspan="1" colspan="1">progressive unsteadiness walking</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles</td>
                <td align="left" rowspan="1" colspan="1">atrophy and weakness of the hand muscles or distal four limbs</td>
                <td align="left" rowspan="1" colspan="1">leukoencephalopathy, lactic acidosis and myalgia</td>
                <td align="left" rowspan="1" colspan="1">fatigue, exercise-lactic acidosis, mild cardiomyopathy</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Functional studies</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1">MRC enzymology, immunoblotting for <italic>GARS</italic> protein and subunits for MRC enzyme complexes</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t001fn001">
            <p>ND = not done; NSânot stated; CD: Catalytic domain, DI: dimer interface, WD: WHEP domain, Ins I: Insertion I domain, Ins II: Insertion II domain, Ins III: Insertion III domain, ACBD: anticodon binding domain; AD: autosomal dominant, AR: autosomal recessive; CMT2: Charcot-Marie-Tooth hereditary neuropathy type 2; CMT2D: upper limb predominant CMT2; SMA: Spinal muscular atrophy; dSMA: distal SMA, dHMN: distal hereditary motor neuropathy type V, MRC: Mitochondrial respiratory chain, MRCD: Mitochondrial respiratory chain disorder.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>However, McMillan and colleagues reported compound heterozygous variants in <italic>GARS</italic> for the first time, in a 12-year old girl with clinical manifestations suggestive of mitochondrial disease, including exercise-induced myalgia, non-compaction cardiomyopathy, lactic acidaemia, and abnormal T2 and T2 FLAIR hyperintensities in the periventricular and trigonal white matter bilaterally on magnetic resonance imaging (MRI)[<xref rid="pone.0178125.ref013" ref-type="bibr">13</xref>]. Herewith, we report the identification of compound heterozygous variants in the <italic>GARS</italic> gene in a 16 year-old female who presented with exercise-intolerance, mild cardiomyopathy and lactic acidosis. Also, our patient had clear evidence of a MRC enzyme deficiency, supporting an expansion of the phenotypic spectrum associated with <italic>GARS</italic> mutations to include mitochondrial disease in cases of autosomal recessive inheritance.</p>
    </sec>
    <sec id="sec002">
      <title>Material and methods</title>
      <sec id="sec003">
        <title>Patient clinical summary</title>
        <p>The proband is a 16 year-old female of non-consanguineous Caucasian origin of British descent. She is the elder of two siblings with each parent being of elite athletic calibre (one represented their country in the Olympics). Difficulty with exercise was first noted at the age of 6 years when the proband started vomiting and became pale and lethargic on a cross-country walk. An echocardiogram and a 24 Holter assessment at the age of 9 years were normal. At this time, she completed isotonic exercise tests using the standard Bruce protocol, completing 8 minutes and 35 seconds, stopping due to breathlessness and a âsore chest.â She reached her anaerobic threshold early at 2.03 minutes with VO<sub>2</sub> max being 57% of predicted. At 11 years of age, the Bruce exercise test was repeated by an exercise physiologist. She fatigued at 6.12 minutes having a VO<sub>2</sub> max of 16.8 ml/kg/min (37% of predicted), with a very high respiratory exchange ratio (VCO<sub>2</sub> /VO<sub>2</sub>) of 1.6.</p>
        <p>The respiratory exchange ratio increases with increasing exercise intensity and is an indirect reflection of proportion of energy derived from carbohydrate metabolism vs. lipid oxidation. The high respiratory exchange ratio was consistent with CHO metabolism as the predominant energy source [<xref rid="pone.0178125.ref014" ref-type="bibr">14</xref>]. A respiratory exchange ratio &gt; 1.1 is generally accepted as indicative of maximal exercise in adults and &gt;1.0 in children [<xref rid="pone.0178125.ref015" ref-type="bibr">15</xref>]. Also, she had a low O<sub>2</sub> pulse (defined as VO<sub>2</sub>/heart rate) of 3 mL/beat (41% of predicted) and a high ventilatory equivalent for O<sub>2</sub> (as defined by VE/VO<sub>2</sub>) of 78 (169% of predicted), both of which are hallmarks of mitochondrial myopathy. Pre-exercise serum lactate was 2.7 mmol/L while after exercise this was 7.0 mmol/L (ref 0â2.0 mmol/L), with a ratio to pyruvate of 70. MRC enzyme assays were consequently performed demonstrating low Complex I, III and IV activity in skeletal muscle (18%, 17%, and 1% relative to citrate synthase respectively) and low Complex I and IV in liver (53% and 6% relative to citrate synthase respectively). There was no evidence of mitochondrial DNA depletion, deletion or duplications in these samples.</p>
        <p>She performs academically well in mainstream education and participates recreationally in sailing. Systemic examination has been normal, in particular with normal tone, power and deep tendon jerk reflexes. She is post pubertal with weight on 40th percentile and height on 75th percentile. Electrolytes, liver function tests, full blood count and clotting, have been normal. At the age of 14 years, mild left ventricular posterior wall hypertrophy was identified measuring 13 mm with normal function.</p>
      </sec>
      <sec id="sec004">
        <title>Exome sequencing</title>
        <p>Genomic DNA was isolated from whole blood of the proband and both parents. Exome capture and library preparation was performed using the Nextera Rapid Capture kit (Illumina, San Diego, CA). Captured libraries were sequenced on an Illumina HiSeq 2000 (2 Ã100 nucleotides) to a depth such that a minimum 80% of targeted bases were sequenced to a read depth of 0020Ã or greater. Reads were aligned to the reference human genome (GRCh37) using BWA-MEM [<xref rid="pone.0178125.ref016" ref-type="bibr">16</xref>], and pedigree informed variant calling was performed using the Real Time Genomics (Hamilton, New Zealand) integrated analysis tool rtgFamily v3.6.2 [<xref rid="pone.0178125.ref017" ref-type="bibr">17</xref>]. All variants were annotated using SnpEff v4.2 [<xref rid="pone.0178125.ref018" ref-type="bibr">18</xref>], SnpEff GRCh37.72 database, dbSNP138, and dbNSFP v2.9. Rare variants (MAF &lt;0.01) were identified and assessed as previously described for their potential to disrupt protein function under different inheritance models using a custom-built interpretation interface incorporating evidence including minor allele frequency, conservation, predicted pathogenicity, and disease association [<xref rid="pone.0178125.ref019" ref-type="bibr">19</xref>].</p>
      </sec>
      <sec id="sec005">
        <title>Variant validation</title>
        <p>The <italic>GARS</italic> variants identified by WES analysis were confirmed by Sanger sequencing of DNA in the proband and her parents, using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit, and ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).</p>
      </sec>
      <sec id="sec006">
        <title>In silico analyses</title>
        <p><italic>In silico</italic> analyses of the <italic>GARS</italic> variants were performed using PolyPhen2 (<ext-link ext-link-type="uri" xlink:href="http://www.genetics.bwh.harvard.edu/pph2/">http://www.genetics.bwh.harvard.edu/pph2/</ext-link>), SIFT (<ext-link ext-link-type="uri" xlink:href="http://www.sift.jcvi.org">http://www.sift.jcvi.org</ext-link>), MutationTaster (<ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org/">www.mutationtaster.org/</ext-link>), GVGD (<ext-link ext-link-type="uri" xlink:href="http://www.agvgd.iarc.fr/">www.agvgd.iarc.fr/</ext-link>), PhyloP (<ext-link ext-link-type="uri" xlink:href="http://www.ccg.vital-it.ch/mga/hg19/phylop">www.ccg.vital-it.ch/mga/hg19/phylop</ext-link>), PhastCons (<ext-link ext-link-type="uri" xlink:href="http://www.compgen.bscb.cornell.edu">www.compgen.bscb.cornell.edu</ext-link>), ExAC (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>) and HOPE (<ext-link ext-link-type="uri" xlink:href="http://www.cmbi.ru.nl/hope">http://www.cmbi.ru.nl/hope</ext-link>).</p>
      </sec>
      <sec id="sec007">
        <title>Immunoblotting</title>
        <p>Immunoblotting was performed as previously described [<xref rid="pone.0178125.ref020" ref-type="bibr">20</xref>], with the following modifications. Membranes were probed with 1:500 anti-OXPHOS (ab110411, Abcam) for 2 h at room temperature or with 1:1000 anti-GARS (ab89522, Abcam) overnight at 4Â°C. Protein loading was normalised to porin (1:5,000 anti-porin, ab14734, Abcam) for 2 h at room temperature. Densitometry was performed as previously described [<xref rid="pone.0178125.ref020" ref-type="bibr">20</xref>].</p>
      </sec>
      <sec id="sec008">
        <title>Spectrophotometric MRC enzyme activity</title>
        <p>MRC enzyme activities in liver and skeletal muscle biopsies from the patient were determined as previously described [<xref rid="pone.0178125.ref021" ref-type="bibr">21</xref>].</p>
        <sec id="sec009">
          <title>Complex I and IV dipstick enzyme activity assays in fibroblasts</title>
          <p>Complex I and IV dipstick enzyme activities were determined as previously described [<xref rid="pone.0178125.ref020" ref-type="bibr">20</xref>].</p>
        </sec>
      </sec>
      <sec id="sec010">
        <title>Statistical analyses</title>
        <p>Graphpad Prism 5.03 was used for all statistical analyses. Statistical analyses were performed using the non-parametric Mann-Whitney <italic>U</italic> test. A <italic>P</italic> value less than 0.05 was considered to be statistically significant.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec011">
      <title>Results</title>
      <p>The presence of exercise intolerance and lactic acidosis in our patient led to an initial evaluation of MRC enzymology in skeletal muscle and liver extracts. Complex IV activity was almost undetectable in skeletal muscle, with a marked deficiency of Complex I and Complex III, suggestive of a defect in mitochondrial DNA maintenance or expression (<xref rid="pone.0178125.t002" ref-type="table">Table 2</xref>). In the liver, Complex IV activity was markedly deficient and Complex I activity borderline low. Complex II and citrate synthase were elevated in both muscle and liver (<xref rid="pone.0178125.t002" ref-type="table">Table 2</xref>). Additionally, we evaluated the activity of the MRC complexes I and IV in patient fibroblast extracts where we observed that the % residual activity relative to protein (% protein) were 75% (P = 0.0004) in Complex I and 45% (P &lt; 0.0001) in Complex IV, compared to controls (<xref rid="pone.0178125.t003" ref-type="table">Table 3</xref>). These results were consistent with the MRC enzymology results in patient skeletal muscle and liver homogenates, although the MRC deficiency was not as severe in fibroblasts.</p>
      <table-wrap id="pone.0178125.t002" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>Spectrophotometric MRC enzyme diagnostic data in skeletal muscle, liver and fibroblasts.</title>
          <p>Patient liver and muscle samples. Data are expressed as activity relative to protein and as % CS ratio, which represents % of the normal control mean value when expressed relative to Citrate Synthase. Bold characters indicate clinically significant abnormal values (Hâhigh, Lâlow). Complex I (CI), NADH-coenzyme Q1 oxidoreductase; Complex II (CII), succinate-coenzyme Q1 oxidoreductase; Complex III (CIII), decylbenzylquinol-cytochrome c oxidoreductase; Complex IV, cytochrome c oxidase (CIV).</p>
        </caption>
        <alternatives>
          <graphic id="pone.0178125.t002g" xlink:href="pone.0178125.t002"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="center" colspan="2" rowspan="1">Enzyme Activity</th>
                <th align="center" colspan="2" rowspan="1">% CS Ratio</th>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1">Muscle</th>
                <th align="center" rowspan="1" colspan="1">Patient</th>
                <th align="center" rowspan="1" colspan="1">(Ref Range)</th>
                <th align="center" rowspan="1" colspan="1">Patient</th>
                <th align="center" rowspan="1" colspan="1">(Ref Range)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">CI (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">18</td>
                <td align="center" rowspan="1" colspan="1">19â72</td>
                <td align="center" rowspan="1" colspan="1">18 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">36â269</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CII (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">142 <bold>H</bold></td>
                <td align="center" rowspan="1" colspan="1">26â63</td>
                <td align="center" rowspan="1" colspan="1">126</td>
                <td align="center" rowspan="1" colspan="1">52â156</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CIII (/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">13.1</td>
                <td align="center" rowspan="1" colspan="1">12.8â50.9</td>
                <td align="center" rowspan="1" colspan="1">17 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">62â185</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CIV (/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">0.21 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">3.3â9.1</td>
                <td align="center" rowspan="1" colspan="1">1 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">36â192</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CS (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">320 <bold>H</bold></td>
                <td align="center" rowspan="1" colspan="1">85â179</td>
                <td align="center" rowspan="1" colspan="1">-</td>
                <td align="center" rowspan="1" colspan="1">-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Liver</bold>
                </td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CI (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">6</td>
                <td align="center" rowspan="1" colspan="1">8â11</td>
                <td align="center" rowspan="1" colspan="1">53</td>
                <td align="center" rowspan="1" colspan="1">65â137</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CII (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">116 <bold>H</bold></td>
                <td align="center" rowspan="1" colspan="1">54â73</td>
                <td align="center" rowspan="1" colspan="1">158</td>
                <td align="center" rowspan="1" colspan="1">59â127</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CIII (/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">11.7</td>
                <td align="center" rowspan="1" colspan="1">5.2â10.3</td>
                <td align="center" rowspan="1" colspan="1">127</td>
                <td align="center" rowspan="1" colspan="1">77â127</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CIV (/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">0.05 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">0.5â0.9</td>
                <td align="center" rowspan="1" colspan="1">6 <bold>L</bold></td>
                <td align="center" rowspan="1" colspan="1">75â134</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CS (nmol/min/mg)</td>
                <td align="center" rowspan="1" colspan="1">33</td>
                <td align="center" rowspan="1" colspan="1">26â31</td>
                <td align="center" rowspan="1" colspan="1">-</td>
                <td align="center" rowspan="1" colspan="1">-</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <table-wrap id="pone.0178125.t003" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.t003</object-id>
        <label>Table 3</label>
        <caption>
          <title>Dipstick MRC enzyme data from cultured fibroblasts.</title>
          <p>Enzyme activity data are expressed as % residual activity relative to protein (% protein).</p>
        </caption>
        <alternatives>
          <graphic id="pone.0178125.t003g" xlink:href="pone.0178125.t003"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1"/>
                <th align="center" colspan="2" rowspan="1">Enzyme Activity %</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Skin fibroblasts</th>
                <th align="center" rowspan="1" colspan="1">Patient</th>
                <th align="center" rowspan="1" colspan="1">Control</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">Complex I</td>
                <td align="center" rowspan="1" colspan="1">75% (p = 0.0004)</td>
                <td align="center" rowspan="1" colspan="1">100%</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Complex IV</td>
                <td align="center" rowspan="1" colspan="1">45% (p &lt; 0.0001)</td>
                <td align="center" rowspan="1" colspan="1">100%</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>Mitochondrial deletion/duplication screening was undertaken, but no structural abnormalities of the mitochondrial genome were identified. Thus, we performed whole exome sequencing and identified compound heterozygous variants, c.803C&gt;T [p.(Thr268Ile), rs2230310] and c.1234C&gt;T [p.(Arg412Cys), rs770924455], in <italic>GARS</italic> (NM_002047.3). Sanger sequencing, with each parent carrying one of the mutations (<xref ref-type="fig" rid="pone.0178125.g001">Fig 1A and 1B</xref>) confirmed both variants. Similarly, to the previous study by McMillan et al. (2014), neither parent showed symptoms or signs of CMT2D or dSMA-V, which are associated with autosomal dominant <italic>GARS</italic> mutations, but this has not been formally excluded by nerve conduction studies.</p>
      <fig id="pone.0178125.g001" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <p><bold>A</bold>) Sanger sequencing profile of <italic>GARS</italic> from the proband and parents showing c.803C&gt;T; p.(Thr268Ile) variant is heterozygous in the proband and the father. <bold>B)</bold> Sanger sequencing profile of <italic>GARS</italic> from the proband and parents showing c.1234C&gt;T; p.(Arg412Cys) variant is heterozygous in the proband and the mother. <bold>C)</bold> Evolutionary sequence conservations of the altered amino acid residues p.Thr268 and p. Arg412 are denoted in bold red in boxes.</p>
        </caption>
        <graphic xlink:href="pone.0178125.g001"/>
      </fig>
      <p>Both variants were considered rare with the minor allele frequency of the c.803C&gt;T variant being 0.0031 and for the c.1234C&gt;T variant being 0.000016 in the ExAC database (<xref rid="pone.0178125.t004" ref-type="table">Table 4</xref>). <italic>In silico</italic> review of both variants (c.803C&gt;T and c.1234C&gt;T) predicted them to affect protein function with the most damaging score by SIFT, PolyPhen-2, Mutation-Taster and GVGD (<xref rid="pone.0178125.t004" ref-type="table">Table 4</xref>).</p>
      <table-wrap id="pone.0178125.t004" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.t004</object-id>
        <label>Table 4</label>
        <caption>
          <title><italic>In silico</italic> analyses of the GARS variants identified in this study.</title>
        </caption>
        <alternatives>
          <graphic id="pone.0178125.t004g" xlink:href="pone.0178125.t004"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" colspan="3" rowspan="1"/>
                <th align="center" colspan="2" rowspan="1">Position</th>
                <th align="center" colspan="4" rowspan="1">Pathogenicity prediction</th>
                <th align="center" colspan="2" rowspan="1">Grade of conservation</th>
                <th align="left" colspan="3" rowspan="1"/>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1">Patient</th>
                <th align="left" rowspan="1" colspan="1">Gene</th>
                <th align="left" rowspan="1" colspan="1">Exon</th>
                <th align="left" rowspan="1" colspan="1">cDNA</th>
                <th align="left" rowspan="1" colspan="1">Protein</th>
                <th align="left" rowspan="1" colspan="1">Sift</th>
                <th align="left" rowspan="1" colspan="1">GVGD</th>
                <th align="left" rowspan="1" colspan="1">Polyphen-2</th>
                <th align="left" rowspan="1" colspan="1">Mutationtster</th>
                <th align="left" rowspan="1" colspan="1">PhyloP</th>
                <th align="left" rowspan="1" colspan="1">PhastCons</th>
                <th align="left" rowspan="1" colspan="1">MAF (ExAC)</th>
                <th align="left" rowspan="1" colspan="1">Genotype</th>
                <th align="left" rowspan="1" colspan="1">Inheritance</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="2" colspan="1">
                  <bold>Proband</bold>
                </td>
                <td align="left" rowspan="2" colspan="1">
                  <bold>GARS</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>7</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>c.803C&gt;T</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>p.(Thr268Ile)</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Damaging</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Class C65 (most likely)</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Probably damaging</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>disease causing</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>4.754</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>1.00</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>0.003174</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Heterozygous</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Paternal</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>10</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>c.1234C&gt;T</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>p.(Arg412Cys)</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Damaging</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Class C65 (most likely)</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Probably damaging</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>disease causing</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>1.78</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>1.00</bold>
                </td>
                <td align="char" char="." rowspan="1" colspan="1">
                  <bold>0.000016</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Heterozygous</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>Maternal</bold>
                </td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="t004fn001">
            <p>N/A: not applicable; MAF: minor allele frequency; PhyloP: values vary between -14 and +6 (Sites predicted to be conserved are assigned positive scores); PhastCons: values vary between 0 and 1. The closer the value is to 1, the more probable the nucleotide is conserve.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Both amino acid positions (p.Thr268 and p.Arg412) are highly conserved across many species (<xref ref-type="fig" rid="pone.0178125.g001">Fig 1C</xref>). <italic>In silico</italic> modelling predicted the amino acid changes (p.Thr268Ile and p.Arg412Cys) to affect the overall chemical and physical properties of the <italic>GARS</italic> protein (<ext-link ext-link-type="uri" xlink:href="http://www.cmbi.ru.nl/hope/">http://www.cmbi.ru.nl/hope/</ext-link>). Both Thr268 and Arg 412 lie in the catalytic domain that synthesizes glycyl adenylate and transfers glycine to its cognate tRNA [<xref rid="pone.0178125.ref022" ref-type="bibr">22</xref>]. Thus, mutations in these positions are likely to disturb the protein synthesis process (<ext-link ext-link-type="uri" xlink:href="http://www.cmbi.ru.nl/hope/">http://www.cmbi.ru.nl/hope/</ext-link>). The wild-type residue Thr268 is smaller and less hydrophobic compared to the mutant amino acid (Ile), while the wild-type residue Arg 412 is larger, positively charged, and less hydrophobic compared to the neutral mutant amino acid, Cys (<ext-link ext-link-type="uri" xlink:href="http://www.cmbi.ru.nl/hope/">http://www.cmbi.ru.nl/hope/</ext-link>) (<xref ref-type="fig" rid="pone.0178125.g002">Fig 2</xref>).</p>
      <fig id="pone.0178125.g002" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>Relative position and conservation of GARS mutations.</title>
          <p>Model of GARS protein structure showing catalytic domain (blue) and anticodon binding domain (grey). Residues mutated in the proband are displayed as red (Thr268) and green (Arg412) spheres. ATP (sticks) and glycine (orange spheres) are seen in the active site pocket. Pink and purple residues indicate previously reported pathogenic mutations in CMT2D and dSMA-V respectively [<xref rid="pone.0178125.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0178125.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0178125.ref028" ref-type="bibr">28</xref>]. Model based on PDB structure 2ZT7.</p>
        </caption>
        <graphic xlink:href="pone.0178125.g002"/>
      </fig>
      <p>Since GARS is required for synthesis of mitochondrial DNA-encoded subunits of Complex I, III, IV and V, we examined GARS protein levels and its pathogenic effect on MRC enzyme complex levels in patient fibroblast extracts. Immunoblot analysis revealed a 300% reduction in GARS protein levels in patient fibroblasts compared to a healthy control using ImageJ version 1.49 [<xref rid="pone.0178125.ref023" ref-type="bibr">23</xref>] (<xref ref-type="fig" rid="pone.0178125.g003">Fig 3A</xref>). Immunoblot analysis of one subunit from each MRC enzyme complex revealed undetectable levels of the mitochondrial DNA-encoded Complex IV COXII subunit in patient fibroblasts, with no reduction in the levels of the other complexes, (<xref ref-type="fig" rid="pone.0178125.g003">Fig 3B</xref>).</p>
      <fig id="pone.0178125.g003" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0178125.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <p><bold>A)</bold> Immunoblot analysis of cultured fibroblasts lysates indicated reduction in expression of GARS protein in patient (P) compared to control (C). Samples containing 20 Î¼g of total protein per lane were loaded in duplicate. Porin was used as a loading control. <bold>B)</bold> Each data point is immunoblot showing OXPHOS expression in cultured fibroblasts from the proband (P) compared to controls (C) in duplicate with a total of 30 Î¼g of protein in each lane. Porin was used as a loading control.</p>
        </caption>
        <graphic xlink:href="pone.0178125.g003"/>
      </fig>
    </sec>
    <sec sec-type="conclusions" id="sec012">
      <title>Discussion</title>
      <p>Here we report the identification of compound heterozygous <italic>GARS</italic> variants in a patient with exercise-intolerance, mild cardiomyopathy and lactic acidosis. <italic>GARS</italic> encodes both cytoplasmic and mitochondrial glycyl-tRNA synthetases which are required for protein synthesis in their respective subcellular locations [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>]. Previous reports of <italic>GARS</italic> mutations have largely been autosomal dominant mutations associated with neuromuscular symptoms including atrophy and weakness of the hand muscles [<xref rid="pone.0178125.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0178125.ref005" ref-type="bibr">5</xref>â<xref rid="pone.0178125.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0178125.ref024" ref-type="bibr">24</xref>]. This phenotype closely resembles those caused by autosomal dominant mutations in cytoplasmic ARS, such as <italic>AARS</italic> (OMIM: 613287), <italic>HARS</italic> (OMIM: 616625), <italic>YARS</italic> (OMIM: 608323) and <italic>MARS</italic> (OMIM: 616280), which have been associated with distal motor neuropathy or polyneuropathies in children and adults [<xref rid="pone.0178125.ref013" ref-type="bibr">13</xref>]. It is thus likely that the neuropathic phenotype in autosomal dominant <italic>GARS</italic> is due to effects on the cytoplasmic GARS rather than mitochondrial GARS, although possible effects on mitochondrial GARS have not been investigated in these cases.</p>
      <p>There is only one previously reported case of autosomal recessive inheritance in <italic>GARS</italic> where the patient displayed some clinical features similar to those seen in our patient. McMillan and colleagues reported a 12-year old girl with clinical and some biochemical features of a systemic mitochondrial disease including exercise-induced myalgia, non-compaction cardiomyopathy, persistent elevation of blood lactate, and white matter changes on brain MRI, who had compound heterozygous mutations (c.1904C&gt;T; p.Ser635Leu and c.1787G&gt;A; p.Arg596Gln) in <italic>GARS</italic> [<xref rid="pone.0178125.ref013" ref-type="bibr">13</xref>]. Neither patient with compound heterozygous variations in <italic>GARS</italic> displayed neuropathy but rather had clinical features which more closely resembled those caused by mutations in mitochondrial ARS. Mitochondrial ARS mutations are associated with a wide phenotypic spectrum, but clinical features may include leukoencephalopathy, cardiomyopathy and lactic acidosis [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>].</p>
      <p>Patients with compound heterozygous <italic>GARS</italic> variants also share some phenotypic overlap with patients reported to have variants in <italic>MT-TG</italic>, which encodes mt-tRNA<sup>Gly</sup>, the cognate tRNA that mitochondrial GARS attaches to glycine. <italic>MT-TG</italic> variants have been associated with hypertrophic cardiomyopathy and exercise intolerance [<xref rid="pone.0178125.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0178125.ref026" ref-type="bibr">26</xref>].</p>
      <p>Mitochondrial ARS mutations mainly affect mitochondrial protein synthesis [<xref rid="pone.0178125.ref002" ref-type="bibr">2</xref>]. Our patient displayed reduced activity of Complex I, III and IV in skeletal muscle consistent with a mitochondrial protein synthesis defect, as a number of subunits of these complexes are mitochondrially encoded. There appeared to be some tissue specific effects, with liver and fibroblasts less affected. The reduced activity of MRC complexes most likely resulted from the reduced levels and/or activity of GARS. Immunoblotting revealed a reduction in the level of the GARS protein in the patient fibroblasts, consistent with the <italic>in silico</italic> predictions, and suggests that the mutant GARS is less stable. Given that both variants are in the catalytic domain, it is also likely that the residual GARS have reduced activity.</p>
      <p>Our results suggest the mitochondrial function of GARS is affected by the compound heterozygous variants we identified in the patient. While the clinical features of the McMillan case were consistent with a mitochondrial disorder, no evidence of a mitochondrial protein synthesis defect was presented and the patient had normal MRC enzyme activities in muscle [<xref rid="pone.0178125.ref013" ref-type="bibr">13</xref>].</p>
      <p>The difference in GARS phenotypes observed in cases of autosomal dominant versus autosomal recessive inheritance may be a consequence of gain of function versus loss of function effects of the mutations [<xref rid="pone.0178125.ref024" ref-type="bibr">24</xref>]. In a mouse study, dominant mutations in <italic>Gars</italic> caused gain of function, with a neuropathic phenotype that could not be corrected by overexpression of wild-type <italic>Gars</italic>. Mice with homozygous <italic>Gars</italic> mutations or a missense mutation in combination with a null allele, displayed a more severe neurological phenotype resulting from loss of function [<xref rid="pone.0178125.ref024" ref-type="bibr">24</xref>]. In our study, we have demonstrated that the compound heterozygous <italic>GARS</italic> variants are also associated with loss of function. In summary, the compound heterozygous <italic>GARS</italic> variants identified in our patient resulted in reduced GARS protein levels and MRC enzyme deficiency. We recommend <italic>GARS</italic> should be added to the list of genes that should be considered in cases of exercise-intolerance and lactic acidosis.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank the Queensland Center for Medical Genomics and the IMB Sequencing Core for their assistance. This research was supported by Australian NHMRC grant 1026891 to J.C., an NHMRC Principal Research Fellowship to D.R.T., and an Australian Mitochondrial Disease Foundation (AMDF) PhD Scholarship to M.N. Finally, we also gratefully acknowledge donations to J.C. by the Crane and Perkins families.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0178125.ref001">
        <label>1</label>
        <mixed-citation publication-type="journal"><name><surname>Kawakami</surname><given-names>N</given-names></name>, <name><surname>Komatsu</surname><given-names>K</given-names></name>, <name><surname>Yamashita</surname><given-names>H</given-names></name>, <name><surname>Uemura</surname><given-names>K</given-names></name>, <name><surname>Oka</surname><given-names>N</given-names></name>, <name><surname>Takashima</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2014</year>) [<article-title>A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement</article-title>]. <source>Rinsho Shinkeigaku</source>
<volume>54</volume>: <fpage>911</fpage>â<lpage>915</lpage>. <?supplied-pmid 25420567?><pub-id pub-id-type="pmid">25420567</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref002">
        <label>2</label>
        <mixed-citation publication-type="journal"><name><surname>Diodato</surname><given-names>D</given-names></name>, <name><surname>Ghezzi</surname><given-names>D</given-names></name>, <name><surname>Tiranti</surname><given-names>V</given-names></name> (<year>2014</year>) <article-title>The Mitochondrial Aminoacyl tRNA Synthetases: Genes and Syndromes</article-title>. <source>Int J Cell Biol</source>
<volume>2014</volume>: <fpage>787956</fpage>
<pub-id pub-id-type="doi">10.1155/2014/787956</pub-id>
<?supplied-pmid 24639874?><pub-id pub-id-type="pmid">24639874</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref003">
        <label>3</label>
        <mixed-citation publication-type="journal"><name><surname>Grice</surname><given-names>SJ</given-names></name>, <name><surname>Sleigh</surname><given-names>JN</given-names></name>, <name><surname>Motley</surname><given-names>WW</given-names></name>, <name><surname>Liu</surname><given-names>JL</given-names></name>, <name><surname>Burgess</surname><given-names>RW</given-names></name>, <name><surname>Talbot</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Dominant, toxic gain-of-function mutations in gars lead to non-cell autonomous neuropathology</article-title>. <source>Hum Mol Genet</source>
<volume>24</volume>: <fpage>4397</fpage>â<lpage>4406</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv176</pub-id>
<?supplied-pmid 25972375?><pub-id pub-id-type="pmid">25972375</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref004">
        <label>4</label>
        <mixed-citation publication-type="journal"><name><surname>Motley</surname><given-names>WW</given-names></name>, <name><surname>Talbot</surname><given-names>K</given-names></name>, <name><surname>Fischbeck</surname><given-names>KH</given-names></name> (<year>2010</year>) <article-title>GARS axonopathy: not every neuron's cup of tRNA</article-title>. <source>Trends Neurosci</source>
<volume>33</volume>: <fpage>59</fpage>â<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2009.11.001</pub-id>
<?supplied-pmid 20152552?><pub-id pub-id-type="pmid">20152552</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref005">
        <label>5</label>
        <mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>YC</given-names></name>, <name><surname>Liu</surname><given-names>YT</given-names></name>, <name><surname>Tsai</surname><given-names>PC</given-names></name>, <name><surname>Chang</surname><given-names>CC</given-names></name>, <name><surname>Huang</surname><given-names>YH</given-names></name>, <name><surname>Soong</surname><given-names>BW</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Two Novel De Novo GARS Mutations Cause Early-Onset Axonal Charcot-Marie-Tooth Disease</article-title>. <source>PLoS One</source>
<volume>10</volume>: <fpage>e0133423</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0133423</pub-id>
<?supplied-pmid 26244500?><pub-id pub-id-type="pmid">26244500</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref006">
        <label>6</label>
        <mixed-citation publication-type="journal"><name><surname>Antonellis</surname><given-names>A</given-names></name>, <name><surname>Ellsworth</surname><given-names>RE</given-names></name>, <name><surname>Sambuughin</surname><given-names>N</given-names></name>, <name><surname>Puls</surname><given-names>I</given-names></name>, <name><surname>Abel</surname><given-names>A</given-names></name>, <name><surname>Lee-Lin</surname><given-names>SQ</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V</article-title>. <source>Am J Hum Genet</source>
<volume>72</volume>: <fpage>1293</fpage>â<lpage>1299</lpage>. <pub-id pub-id-type="doi">10.1086/375039</pub-id>
<?supplied-pmid 12690580?><pub-id pub-id-type="pmid">12690580</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref007">
        <label>7</label>
        <mixed-citation publication-type="journal"><name><surname>Sivakumar</surname><given-names>K</given-names></name>, <name><surname>Kyriakides</surname><given-names>T</given-names></name>, <name><surname>Puls</surname><given-names>I</given-names></name>, <name><surname>Nicholson</surname><given-names>GA</given-names></name>, <name><surname>Funalot</surname><given-names>B</given-names></name>, <name><surname>Antonellis</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations</article-title>. <source>Brain</source>
<volume>128</volume>: <fpage>2304</fpage>â<lpage>2314</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awh590</pub-id>
<?supplied-pmid 16014653?><pub-id pub-id-type="pmid">16014653</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref008">
        <label>8</label>
        <mixed-citation publication-type="journal"><name><surname>James</surname><given-names>PA</given-names></name>, <name><surname>Cader</surname><given-names>MZ</given-names></name>, <name><surname>Muntoni</surname><given-names>F</given-names></name>, <name><surname>Childs</surname><given-names>AM</given-names></name>, <name><surname>Crow</surname><given-names>YJ</given-names></name>, <name><surname>Talbot</surname><given-names>K</given-names></name> (<year>2006</year>) <article-title>Severe childhood SMA and axonal CMT due to anticodon binding domain mutations in the GARS gene</article-title>. <source>Neurology</source>
<volume>67</volume>: <fpage>1710</fpage>â<lpage>1712</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000242619.52335.bc</pub-id>
<?supplied-pmid 17101916?><pub-id pub-id-type="pmid">17101916</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref009">
        <label>9</label>
        <mixed-citation publication-type="journal"><name><surname>Rohkamm</surname><given-names>B</given-names></name>, <name><surname>Reilly</surname><given-names>MM</given-names></name>, <name><surname>Lochmuller</surname><given-names>H</given-names></name>, <name><surname>Schlotter-Weigel</surname><given-names>B</given-names></name>, <name><surname>Barisic</surname><given-names>N</given-names></name>, <name><surname>Schols</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome</article-title>. <source>J Neurol Sci</source>
<volume>263</volume>: <fpage>100</fpage>â<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2007.06.047</pub-id>
<?supplied-pmid 17663003?><pub-id pub-id-type="pmid">17663003</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref010">
        <label>10</label>
        <mixed-citation publication-type="journal"><name><surname>Hamaguchi</surname><given-names>A</given-names></name>, <name><surname>Ishida</surname><given-names>C</given-names></name>, <name><surname>Iwasa</surname><given-names>K</given-names></name>, <name><surname>Abe</surname><given-names>A</given-names></name>, <name><surname>Yamada</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Charcot-Marie-Tooth disease type 2D with a novel glycyl-tRNA synthetase gene (GARS) mutation</article-title>. <source>J Neurol</source>
<volume>257</volume>: <fpage>1202</fpage>â<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-010-5491-x</pub-id>
<?supplied-pmid 20169446?><pub-id pub-id-type="pmid">20169446</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref011">
        <label>11</label>
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name>, <name><surname>Park</surname><given-names>J</given-names></name>, <name><surname>Nakhro</surname><given-names>K</given-names></name>, <name><surname>Park</surname><given-names>JM</given-names></name>, <name><surname>Hur</surname><given-names>YM</given-names></name>, <name><surname>Choi</surname><given-names>BO</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Two novel mutations of GARS in Korean families with distal hereditary motor neuropathy type V</article-title>. <source>J Peripher Nerv Syst</source>
<volume>17</volume>: <fpage>418</fpage>â<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1111/j.1529-8027.2012.00442.x</pub-id>
<?supplied-pmid 23279345?><pub-id pub-id-type="pmid">23279345</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref012">
        <label>12</label>
        <mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>CJ</given-names></name>, <name><surname>Middha</surname><given-names>S</given-names></name>, <name><surname>Duan</surname><given-names>X</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>, <name><surname>Litchy</surname><given-names>WJ</given-names></name>, <name><surname>Gu</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Application of whole exome sequencing in undiagnosed inherited polyneuropathies</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<volume>85</volume>: <fpage>1265</fpage>â<lpage>1272</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2013-306740</pub-id>
<?supplied-pmid 24604904?><pub-id pub-id-type="pmid">24604904</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref013">
        <label>13</label>
        <mixed-citation publication-type="journal"><name><surname>McMillan</surname><given-names>HJ</given-names></name>, <name><surname>Schwartzentruber</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Chakraborty</surname><given-names>P</given-names></name>, <name><surname>Bulman</surname><given-names>DE</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Compound heterozygous mutations in glycyl-tRNA synthetase are a proposed cause of systemic mitochondrial disease</article-title>. <source>BMC Med Genet</source>
<volume>15</volume>: <fpage>36</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-15-36</pub-id>
<?supplied-pmid 24669931?><pub-id pub-id-type="pmid">24669931</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref014">
        <label>14</label>
        <mixed-citation publication-type="journal"><name><surname>Ten Harkel</surname><given-names>AD</given-names></name>, <name><surname>Takken</surname><given-names>T</given-names></name>, <name><surname>Van Osch-Gevers</surname><given-names>M</given-names></name>, <name><surname>Helbing</surname><given-names>WA</given-names></name> (<year>2011</year>) <article-title>Normal values for cardiopulmonary exercise testing in children</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>
<volume>18</volume>: <fpage>48</fpage>â<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1097/HJR.0b013e32833cca4d</pub-id>
<?supplied-pmid 20595902?><pub-id pub-id-type="pmid">20595902</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref015">
        <label>15</label>
        <mixed-citation publication-type="journal"><name><surname>Arena</surname><given-names>R</given-names></name>, <name><surname>Myers</surname><given-names>J</given-names></name>, <name><surname>Williams</surname><given-names>MA</given-names></name>, <name><surname>Gulati</surname><given-names>M</given-names></name>, <name><surname>Kligfield</surname><given-names>P</given-names></name>, <name><surname>Balady</surname><given-names>GJ</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing</article-title>. <source>Circulation</source>
<volume>116</volume>: <fpage>329</fpage>â<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.184461</pub-id>
<?supplied-pmid 17576872?><pub-id pub-id-type="pmid">17576872</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref016">
        <label>16</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>
<volume>25</volume>: <fpage>1754</fpage>â<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>
<?supplied-pmid 19451168?><pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref017">
        <label>17</label>
        <mixed-citation publication-type="journal"><name><surname>Cleary</surname><given-names>JG</given-names></name>, <name><surname>Braithwaite</surname><given-names>R</given-names></name>, <name><surname>Gaastra</surname><given-names>K</given-names></name>, <name><surname>Hilbush</surname><given-names>BS</given-names></name>, <name><surname>Inglis</surname><given-names>S</given-names></name>, <name><surname>Irvine</surname><given-names>SA</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Joint variant and de novo mutation identification on pedigrees from high-throughput sequencing data</article-title>. <source>J Comput Biol</source>
<volume>21</volume>: <fpage>405</fpage>â<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1089/cmb.2014.0029</pub-id>
<?supplied-pmid 24874280?><pub-id pub-id-type="pmid">24874280</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref018">
        <label>18</label>
        <mixed-citation publication-type="journal"><name><surname>Cingolani</surname><given-names>P</given-names></name>, <name><surname>Platts</surname><given-names>A</given-names></name>, <name><surname>Wang le</surname><given-names>L</given-names></name>, <name><surname>Coon</surname><given-names>M</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3</article-title>. <source>Fly (Austin)</source>
<volume>6</volume>: <fpage>80</fpage>â<lpage>92</lpage>.<pub-id pub-id-type="pmid">22728672</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref019">
        <label>19</label>
        <mixed-citation publication-type="journal"><name><surname>Vanderver</surname><given-names>A</given-names></name>, <name><surname>Simons</surname><given-names>C</given-names></name>, <name><surname>Helman</surname><given-names>G</given-names></name>, <name><surname>Crawford</surname><given-names>J</given-names></name>, <name><surname>Wolf</surname><given-names>NI</given-names></name>, <name><surname>Bernard</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Whole exome sequencing in patients with white matter abnormalities</article-title>. <source>Ann Neurol</source>
<volume>79</volume>: <fpage>1031</fpage>â<lpage>1037</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24650</pub-id>
<?supplied-pmid 27159321?><pub-id pub-id-type="pmid">27159321</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref020">
        <label>20</label>
        <mixed-citation publication-type="journal"><name><surname>Nafisinia</surname><given-names>M</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Dang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Whole Exome Sequencing Identifies the Genetic Basis of Late-Onset Leigh Syndrome in a Patient with MRI but Little Biochemical Evidence of a Mitochondrial Disorder</article-title>. <source>JIMD Rep</source>.</mixed-citation>
      </ref>
      <ref id="pone.0178125.ref021">
        <label>21</label>
        <mixed-citation publication-type="journal"><name><surname>Frazier</surname><given-names>AE</given-names></name>, <name><surname>Thorburn</surname><given-names>DR</given-names></name> (<year>2012</year>) <article-title>Biochemical analyses of the electron transport chain complexes by spectrophotometry</article-title>. <source>Methods Mol Biol</source>
<volume>837</volume>: <fpage>49</fpage>â<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-504-6_4</pub-id>
<?supplied-pmid 22215540?><pub-id pub-id-type="pmid">22215540</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref022">
        <label>22</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Macnamara</surname><given-names>LM</given-names></name>, <name><surname>Leuchter</surname><given-names>JD</given-names></name>, <name><surname>Alexander</surname><given-names>RW</given-names></name>, <name><surname>Cho</surname><given-names>SS</given-names></name> (<year>2015</year>) <article-title>MD Simulations of tRNA and Aminoacyl-tRNA Synthetases: Dynamics, Folding, Binding, and Allostery</article-title>. <source>Int J Mol Sci</source>
<volume>16</volume>: <fpage>15872</fpage>â<lpage>15902</lpage>. <pub-id pub-id-type="doi">10.3390/ijms160715872</pub-id>
<?supplied-pmid 26184179?><pub-id pub-id-type="pmid">26184179</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref023">
        <label>23</label>
        <mixed-citation publication-type="other">Rasband WS (1997â2016) ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA.<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>.</mixed-citation>
      </ref>
      <ref id="pone.0178125.ref024">
        <label>24</label>
        <mixed-citation publication-type="journal"><name><surname>Motley</surname><given-names>WW</given-names></name>, <name><surname>Seburn</surname><given-names>KL</given-names></name>, <name><surname>Nawaz</surname><given-names>MH</given-names></name>, <name><surname>Miers</surname><given-names>KE</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Antonellis</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels</article-title>. <source>PLoS Genet</source>
<volume>7</volume>: <fpage>e1002399</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002399</pub-id>
<?supplied-pmid 22144914?><pub-id pub-id-type="pmid">22144914</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref025">
        <label>25</label>
        <mixed-citation publication-type="journal"><name><surname>Merante</surname><given-names>F</given-names></name>, <name><surname>Tein</surname><given-names>I</given-names></name>, <name><surname>Benson</surname><given-names>L</given-names></name>, <name><surname>Robinson</surname><given-names>BH</given-names></name> (<year>1994</year>) <article-title>Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA(glycine) gene</article-title>. <source>Am J Hum Genet</source>
<volume>55</volume>: <fpage>437</fpage>â<lpage>446</lpage>. <?supplied-pmid 8079988?><pub-id pub-id-type="pmid">8079988</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref026">
        <label>26</label>
        <mixed-citation publication-type="journal"><name><surname>Nishigaki</surname><given-names>Y</given-names></name>, <name><surname>Bonilla</surname><given-names>E</given-names></name>, <name><surname>Shanske</surname><given-names>S</given-names></name>, <name><surname>Gaskin</surname><given-names>DA</given-names></name>, <name><surname>DiMauro</surname><given-names>S</given-names></name>, <name><surname>Hirano</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>Exercise-induced muscle "burning," fatigue, and hyper-CKemia: mtDNA T10010C mutation in tRNA(Gly)</article-title>. <source>Neurology</source>
<volume>58</volume>: <fpage>1282</fpage>â<lpage>1285</lpage>. <?supplied-pmid 11971101?><pub-id pub-id-type="pmid">11971101</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref027">
        <label>27</label>
        <mixed-citation publication-type="journal"><name><surname>Del Bo</surname><given-names>R</given-names></name>, <name><surname>Locatelli</surname><given-names>F</given-names></name>, <name><surname>Corti</surname><given-names>S</given-names></name>, <name><surname>Scarlato</surname><given-names>M</given-names></name>, <name><surname>Ghezzi</surname><given-names>S</given-names></name>, <name><surname>Prelle</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Coexistence of CMT-2D and distal SMA-V phenotypes in an Italian family with a GARS gene mutation</article-title>. <source>Neurology</source>
<volume>66</volume>: <fpage>752</fpage>â<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000201275.18875.ac</pub-id>
<?supplied-pmid 16534118?><pub-id pub-id-type="pmid">16534118</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0178125.ref028">
        <label>28</label>
        <mixed-citation publication-type="journal"><name><surname>Abe</surname><given-names>A</given-names></name>, <name><surname>Hayasaka</surname><given-names>K</given-names></name> (<year>2009</year>) <article-title>The GARS gene is rarely mutated in Japanese patients with Charcot-Marie-Tooth neuropathy</article-title>. <source>J Hum Genet</source>
<volume>54</volume>: <fpage>310</fpage>â<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2009.25</pub-id>
<?supplied-pmid 19329989?><pub-id pub-id-type="pmid">19329989</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>